Reuters

The company now expects annual revenue to be near the low end of its prior forecast range of between $2 billion and $2.3 billion

The long-acting therapy, also known as nirsevimab, was given the European Union (EU) marketing authorisation for the prevention of…

The company has been on an acquisition spree in recent months, from buying supplement maker Endura Mass to stake purchases in…

The company did say the 2023 outlook excludes expected contracts with countries such as the US and Japan, and that it anticipated…

The company is in a drawn-out production revamp after a contractor filling Wegovy injection pens ran into problems late last year

Sanofi reported a 26.5 per cent rise in third-quarter business operating income, or adjusted earnings before interest and tax, to…

Chinese regulators approved the vaccine

The agency blamed the delay on pandemic-related travel restrictions that kept it from conducting a required manufacturing site…

The Duke Clinical Research Institute is supervising the study, which is scheduled to start on 1st January

In a late-stage study, the antibody-based drug, otilimab, did not make a meaningful difference to improving swelling and…